Subscribe

GeneReach Biotechnology Corp. (4171.TWO)

TWD17.00 +0.00 (+0.00%)
TW TWO Healthcare Biotechnology
Address Central Science Park 407
Taichung, TW
CEO De Yu Zhong
Website genereach.com
IPO 2012-11-19
ISIN TW0004171004

Explore sections of this company profile

Description

GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD17.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
148.5K
Beta
0.40
Float Shares
35.20M
Free Float %
61.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.28% -1.93% -7.55% -11.03% -11.47% -5.59% -32.12% -58.37% -82.91% -25.01% -40.18%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
17.00
DCF (Unlevered) 0.47 -97.2%
DCF (Levered) 0.39 -97.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.26
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +12.7% ★ Q1'26: -0.4% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    +7.2% Q1'26: +50.0% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -24.4% Q1'26: +0.1% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -34.3% Q1'26: -27.0% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -19.1% Q1'26: -13.9% (vs Q1'25)
  • ✓
    Share dilution Biotechnology: -3.4%
    -0.6% ★ Q1'26: +4.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -2.82× Q1'26: -3.88× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.49) × ERP
WACC = 82% × Ke + 18% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.47 Current price: 17.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
883.66M
est.
150.00M
est.
158.00M
est.
186.00M
est.
365.80M
est: 321.00M (+14.0%)
857.03M
est: 2.09B (-59.0%)
1.01B
est: 925.40M (+9.4%)
750.02M
est: 2.09B (-64.1%)
225.46M
est: 925.40M (-75.6%)
206.49M
est: 150.00M (+37.7%)
232.74M
est: 158.00M (+47.3%)
186.00M
186.00M – 186.00M
+17.7% YoY
321.00M
321.00M – 321.00M
+72.6% YoY
2.09B
2.09B – 2.09B
+551.4% YoY
925.40M
925.40M – 925.40M
-55.7% YoY
925.40M
925.40M – 925.40M
+0.0% YoY
EBITDA
113.31M
est.
19.23M
est.
20.26M
est.
23.85M
est.
132.98M
est: 41.16M (+223.1%)
396.59M
est: 268.13M (+47.9%)
540.70M
est: 118.67M (+355.7%)
343.02M
est: 268.13M (+27.9%)
-143.70M
est: 118.67M (-221.1%)
-36.31M
est: -4.94M (-634.7%)
-79.86M
est: -5.21M (-1,434.3%)
-6.13M
-6.13M – -6.13M
-17.7% YoY
-10.58M
-10.58M – -10.58M
-72.6% YoY
-68.89M
-68.89M – -68.89M
-551.4% YoY
-30.49M
-30.49M – -30.49M
+55.7% YoY
-30.49M
-30.49M – -30.49M
+0.0% YoY
EBIT
-41.17M
est.
-6.99M
est.
-7.36M
est.
-8.67M
est.
111.94M
est: -14.96M (+848.4%)
342.76M
est: -97.43M (+451.8%)
475.63M
est: -43.12M (+1,203.1%)
278.98M
est: -97.43M (+386.3%)
-212.58M
est: -43.12M (-393.0%)
-111.04M
est: -29.35M (-278.3%)
-79.86M
est: -30.92M (-158.3%)
-36.40M
-36.40M – -36.40M
-17.7% YoY
-62.81M
-62.81M – -62.81M
-72.6% YoY
-409.16M
-409.16M – -409.16M
-551.4% YoY
-181.08M
-181.08M – -181.08M
+55.7% YoY
-181.08M
-181.08M – -181.08M
+0.0% YoY
Net Income
99.71M
est.
-26.47M
est.
-32.48M
est.
39.30M
est.
77.18M
est: 97.05M (-20.5%)
257.28M
est: 931.98M (-72.4%)
376.62M
est: 315.61M (+19.3%)
221.34M
est: 931.98M (-76.3%)
-166.27M
est: 315.61M (-152.7%)
-118.73M
est: -26.32M (-351.1%)
-112.93M
est: -32.30M (-249.6%)
39.08M
39.08M – 39.08M
+221.0% YoY
96.51M
96.51M – 96.51M
+146.9% YoY
926.82M
926.82M – 926.82M
+860.3% YoY
313.86M
313.86M – 313.86M
-66.1% YoY
313.86M
313.86M – 313.86M
+0.0% YoY
SGA
408.60M
est.
69.36M
est.
73.06M
est.
86.01M
est.
147.15M
est: 148.43M (-0.9%)
209.27M
est: 966.86M (-78.4%)
202.96M
est: 427.90M (-52.6%)
191.05M
est: 966.86M (-80.2%)
173.98M
est: 427.90M (-59.3%)
173.63M
est: 62.03M (+179.9%)
—
est: 65.34M (-100.0%)
76.92M
76.92M – 76.92M
+17.7% YoY
132.75M
132.75M – 132.75M
+72.6% YoY
864.75M
864.75M – 864.75M
+551.4% YoY
382.71M
382.71M – 382.71M
-55.7% YoY
382.71M
382.71M – 382.71M
+0.0% YoY
EPS
1.74
est.
-0.46
est.
-0.57
est.
0.68
est.
1.41
est: 1.69 (-16.5%)
4.48
est: 16.22 (-72.4%)
6.55
est: 5.49 (+19.2%)
3.85
est: 16.22 (-76.3%)
-2.89
est: 5.49 (-152.6%)
-2.08
est: -0.46 (-351.5%)
-1.93
est: -0.57 (-241.4%)
0.68
0.68 – 0.68
+221.0% YoY
1.69
1.69 – 1.69
+146.9% YoY
16.22
16.22 – 16.22
+860.3% YoY
5.49
5.49 – 5.49
-66.1% YoY
5.49
5.49 – 5.49
+0.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-05-28 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-05-27 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-05-26 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-05-25 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-05-22 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-11 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-08 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-07 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-06 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-05 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-05-04 C 2/5 2/5 1/5 1/5 2/5 1/5 3/5
2026-04-30 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-4.55M
OE per share TTM
-0.07
Owner's Yield
-0.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
71.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-665.5K
Shares Outstanding
57.30M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Zhengzhong Liu Chairman of the Board & Head of Public Relations 8M male
De Yu Zhong CEO & Director — male
Lu Yuan Liu Chief Operating Officer — male
Shuyu Cao Accounting Supervisor — female
Xiu Ying Zhang Treasurer — female
Yu-Wen Huang Vice President of Compliance & Production Department — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology